The aim of this work was to study the pharmacokinetics of piperaquine in healthy volunteers. Healthy volunteers received piperaquine and tablets of Artekin by oral administration. The plasma samples were analyzed for piperaquine by liquid-liquid extraction and determined by HPLC-UV. The results demonstrated that the plasma drug concentrationtime curves of single and multiple dose of piperaquine wereˆtted to a two-compartment open model. The pharmacokinetics parameters of piperaquine alone in a single dose were: t 1/2(b) ＝(317.2-/＋126.6)h, AUC 0→∞ ＝(44293-/＋ 12636)h×ng/ml, V d ＝(9490.9-/＋2161.9)ml/kg, and Cl＝(22.83-/＋9.83)ml/h/kg. In Artekin in a single dose these parameters were: t 1/2(b) ＝(302.8-/＋180.7)h, AUC 0→∞ ＝(46419-/＋13670)h×ng/ml, V d ＝(10188.6-/＋ 3520.3)ml/kg, and Cl＝(25.48-/＋10.89)ml/h/kg, while in Artekin in multiple doses they were: t 1/2(b) ＝(298.9-/＋ 101.9)h, AUC 0→∞ ＝(227692-/＋56294)h×ng/ml, V d ＝(5031.5-/＋1097.8)ml/kg, Cl＝(11.91-/＋3.046)ml/h/kg, respectively. The absorption and distribution of piperaquine were quick while the elimination was quite slow. There were signiˆcant diŠerences in the pharmacokinetics parameters of piperaquine in Artekin between a single dose and multiple doses (p＜0.001), suggesting that piperaquine might accumulate in vivo and that attention should be given to its possible adverse drug reactions in clinical treatment.
INTRODUCTION
Malaria is a common and a life-threatening disease in many tropical and subtropical areas. At present it is the developing world's most dreaded killer, accouting for the deaths of over two million people per year according to estimates by the World Health Organization. 1) Piperaquine {1,3-bis [1-(7-chloro-4′ -quinolyl)-4′ -piperazinyl]; PQ} is an anti-malaria drug which was synthesized in the 1960s. In recent years, PQ and many combination anti-malarial products containing PQ such as Artekin(dihydroartemisinin and PQ phosphate) and CV8(dihydroartemisinin, PQ phosphate, trimethoprim and primaquine), have also been used eŠectively to prevent and treat drug-resistant Plasmodium falciparum. 5 7) Although PQ has been in clinical use for several decades, the information about its pharmacokinetics is scarce. Chen et al. 8) demonstrated that the half-life of PQ was about 9 days in rats. Roshammar et al. 9) reported that the pharmacokinetics of PQ after repeated oral administration of CV8 in healthy subjects were described by a two-compartment disposition model with a terminal half-life of 11.7 days, and Hung et al. 10) pointed out that the population pharmacokinetics of Artekin in adults and children with malaria were described by a two-compartment disposition model, and the half-life was 23 days in adults and 14 days in children. However, those previous studies did not research the pharmacokinetics' diŠer-ences between PQ and PQ in the combination antimalarial drugs nor the diŠerences between male and female. We therefore set out to investigate these diŠerences and develop a safe and rational dose regimen.
EXPERIMENTALS

Chemicals and Reagents
PQ and the internal standard (chliroquine, CQ) were obtained from Guangzhou University of Traditional Chinese Medicine (Guangzhou, China). Acetonitrile (HPLC grade) was purchased from Merck (Darmstadt, Germany) and all other chemicals and solvents were of analytical grade.
Instrumentation and Chromatographic Conditions
The HPLC system used in the assay consisted of a Waters 515 pump and Waters 486 UV detector (Milford, USA). Data acquisition was obtained from Mellinium 32 Chromatography Station (USA). Separations were achieved on an Alltima C 18 column (5-mm, 4.6×100 mm) with a 5-mm SecurityGuard C 18 short guard column (Grace, USA). The mobile phase was acetonitrile 0.1％ trichloroacetic acid solution (w/v) phosphate acid (25:75:0.035, v/v/v) with a ‰ow rate of 0.4 ml/min and UV detected at 345 nm.
Sample Preparation
The volume of a 500 ml plasma sample was pipetted into a 10 ml polypropylene tube and 100 ng CQ added as an internal standard. Two-tenths ml of 1 M NaOH was added followed by 30 s of vortex mixing. PQ was then extracted with 5 ml of diethyl-ether by shaking vigorously for 10 min. After centrifugation at 6000×g for 5 min, the organic (upper) phase was transferred into a clean tube and dried under a stream of nitrogen in a 37°C water bath. The residue was reconstituted in 100 ml of mobile phase and 20 ml was injected into the LC system.
Subjects
Sixteen healthy Chinese volunteers (eight males and eight females) were divided into 2 groups. The characteristics of the male volunteers were: mean age 28.8 years (SD＝2.9), mean weight 66.2 kg (SD＝3.1); the characteristics of the female volunteers were: mean age 26.6 years (SD＝ 3.1), mean weight 53.2 kg (SD＝6.6). None volunteers had smoked or drunk alcohol or coŠee or abused other drugs before or during the study, and informed consent was obtained. This project was approved by the local hospital ethics committee for study.
4-1. Single Dose 4-1-1. PQ after Oral Administration All the healthy volunteers received 640 mg of PQ phosphate, the same quantity as in a tablet of Artekin, at 8 a.m with a glass of water (250 ml) and, 2 hours later, ate a standard meal. Venous blood samples (5 ml) were collected pre-dose and at 0.25, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 168, 336, 504 and 840 h. Samples were placed in heparinized vacutainer tubes and centrifuged at 5000×g for 15 min and the plasma aliquots were transferred to polypropylene tubes and frozen at -37°C until analysis. 
Data Analysis
The results were expressed as šx±s. All data were statistically analyzed by paired t test. Compartmental pharmacokinetic analysis of plasma PQ concentration vs. time data was carried out using PKsolution2 (USA) to estimate the absorption rate constant, apparent volume of distribution, oral clearance, elimination half-life and other pharmacokinetic parameters.
RESULTS
Speciˆcity
PQ and the internal standard CQ eluted at 11.0 and 12.9 min, respectively. There were no interfering peaks in the chromatogram (Fig.  1) .
Linearity, Limits of Quantiˆcation (LOQ) and Limits of Detection (LOD)
There was a good linearity over the range of 20 1000 ng/ml in the plasma and the calibration curve was Y＝0.0254＋ 5.1376x with a correlation coe‹cient of 0.9993. The LOQ for the assay was 20 ng/ml and the LOD was 10 ng/ml.
Precision and Accuracy
The data of precision and accuracy are summarized in Table 1 . The intra-day relative standard deviation (RSDs) and the inter-day RSDs at the concentration of 20, 200, 1000 ng/ml were less than 12.0％ and 11.0％, respectively. The intra-day accuracy ranged from 93.4 106.5％ and the inter-day accuracy ranged from 94.8 103.5％, respectively.
The Pharmacokinetics of PQ
The phar- 
DISCUSSION
In this study, we found that a two-compartment open model could give an optimalˆt to PQ drug concentration-time data. The half-life of PQ was 12.5 days, and its absorption and distribution were quick while elimination was quite slow. It was suggested that PQ was absorbed easily in vivo due to its strong lipophilic chemicals. 10) We also found multiple peak proˆles observed in Fig. 4 in our study. Roshammar et al. 9) believed this phenomenon was caused by gastric emptying.
Comparing the pharmacokinetic parameters of PQ with that of Artekin, we found that there were no signiˆcant diŠerences in single dose (p＞0.05). This indicated that DHA in Artekin did not aŠect or even change PQ's absorption, distribution and elimination inside a human when used clinically. However, there were quite signiˆcant diŠerences in the pharmacokinetic parameters of PQ in Artekin between single dose and multiple doses (p＜0.001). As is clearly shown by Fig. 3 , the value of C max of multiple doses was four times larger than that of a single dose, but the value of V d and Cl of multiple doses were less than these of a single dose. This phenomenon suggested that PQ might accumulate in the human body and that attention should be given to its potential adverse drug reactions in clinical treatment.
Some previous studies reported 11) that the pharmacokinetic parameters of PQ not only diŠerenced in healthy volunteers and patients but also in rats. 8) So the values found in this study were not similar to those obtained from some previous studies. 9 10) Also some studies pointed out 11) that the pharmacokinetic parameters of many kinds of the drug were in‰uenced by human gender. 11) To develop the rational dose regimen of PQ, this study investigated its pharmacokinetic property in male and female. Because there was a diŠerence in the mean body weight in the male and female volunteers in this project (p＜ 0.05), in order to evaluate the diŠerence of pharmacokinetic parameters related to gender, the factor of body weight had to be calculated. Therefore, all the pharmacokinetic parameters were corrected by the body weight (W) and dose (D). Table 4 were obtained from the D/W of female and male and analyzed by single-factor analysis of variance (ANOVA). The results are shown in Table 5 .
The results demonstrated that there were distinct discriminations in the values of correction of pharmacokinetic parameters depending on gender. Namely, there was obvious diŠerence in the parameters of PQ after administration of a single dose of Artekin in male and female healthy volunteers.
